Proteasomal inhibition reduces parkin mRNA in PC12 and SH-SY5Y cells

Parkinsonism and Related Disorders

Volumn 15, Issue 3, 2009, Pages 220-225

  Koch, Andreas ^a   Lehmann Horn, Klaus ^a   Dächsel, Justus C ^a   Gasser, Thomas ^b   Kahle, Philipp J ^b   Lücking, Christoph B ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Dorfin; Parkin; Parkinson's disease; Proteasomal dysfunction; Siah 1; Ubiquitin proteasome system (UPS)

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DORFIN; EPOXOMICIN; MESSENGER RNA; PARKIN; PROTEASOME; PROTEIN SIAH 1; ROTENONE; TUNICAMYCIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; CYTOSOL; GENE; GENE CONTROL; GENE EXPRESSION; NONHUMAN; PACRG GENE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; RAT; UPREGULATION;

EID: 60549112392     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.05.005     Document Type: Article

References (30)

1. Gasser T. Genetics of Parkinson's disease. Curr Opin Neurol 18 (2005) 363-369
2. Tan E.K., and Skipper L.M. Pathogenic mutations in Parkinson disease. Hum Mutat 28 (2007) 641-653
3. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25 (2000) 302-305
4. McNaught K.S., Belizaire R., Isacson O., Jenner P., and Olanow C.W. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179 (2003) 38-46
5. Haywood A.F., and Staveley B.E. Mutant alpha-synuclein-induced degeneration is reduced by parkin in a fly model of Parkinson's disease. Genome 49 (2006) 505-510
6. Lo Bianco C., Schneider B.L., Bauer M., Sajadi A., Brice A., Iwatsubo T., et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci USA 101 (2004) 17,510-17,515
7. Yang H., Zhou H.Y., Li B., and Chen S.D. Neuroprotection of Parkin against apoptosis is independent of inclusion body formation. Neuroreport 16 (2005) 1117-1121
8. Yang Y.X., Muqit M.M., and Latchman D.S. Induction of parkin expression in the presence of oxidative stress. Eur J Neurosci 24 (2006) 1366-1372
9. Jiang H., Ren Y., Zhao J., and Feng J. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 13 (2004) 1745-1754
10. Cha G.H., Kim S., Park J., Lee E., Kim M., Lee S.B., et al. Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc Natl Acad Sci USA 102 (2005) 10,345-10,350
11. Henn I.H., Bouman L., Schlehe J.S., Schlierf A., Schramm J.E., Wegener E., et al. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J Neurosci 27 (2007) 1868-1878
12. Chung K.K., Zhang Y., Lim K.L., Tanaka Y., Huang H., Gao J., et al. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 7 (2001) 1144-1150
13. Ito T., Niwa J., Hishikawa N., Ishigaki S., Doyu M., and Sobue G. Dorfin localizes to Lewy bodies and ubiquitylates synphilin-1. J Biol Chem 278 (2003) 29,106-29,114
14. Liani E., Eyal A., Avraham E., Shemer R., Szargel R., Berg D., et al. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc Natl Acad Sci U S A 101 (2004) 5500-5505
15. Engelender S., Kaminsky Z., Guo X., Sharp A.H., Amaravi R.K., Kleiderlein J.J., et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 22 (1999) 110-114
16. Dächsel J.C., Lücking C.B., Deeg S., Schultz E., Lalowski M., Casademunt E., et al. Parkin interacts with the proteasome subunit alpha4. FEBS Lett 579 (2005) 3913-3919
17. West A.B., Lockhart P.J., O'Farell C., and Farrer M.J. Identification of a novel gene linked to parkin via a bi-directional promoter. J Mol Biol 326 (2003) 11-19
18. Junn E., Lee S.S., Suhr U.T., and Mouradian M.M. Parkin accumulation in aggresomes due to proteasome impairment. J Biol Chem 277 (2002) 47,870-47,877
19. Imai Y., Soda M., and Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 275 (2000) 35,661-35,664
20. West A.B., Gonzalez-de-Chavez F., Wilkes K., O'Farrell C., and Farrer M.J. Parkin is not regulated by the unfolded protein response in human neuroblastoma cells. Neurosci Lett 341 (2003) 139-142
21. Wang H.Q., Imai Y., Kataoka A., and Takahashi R. Cell type-specific upregulation of Parkin in response to ER stress. Antioxid Redox Signal 9 (2007) 533-542
22. Yamamoto A., Friedlein A., Imai Y., Takahashi R., Kahle P.J., and Haass C. Parkin phosphorylation and modulation of its E3 ubiquitin ligase activity. J Biol Chem 280 (2005) 3390-3399
23. McNaught K.S., Perl D.P., Brownell A.L., and Olanow C.W. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56 (2004) 149-162
24. Schapira A.H., Cleeter M.W., Muddle J.R., Workman J.M., Cooper J.M., and King R.H. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol 60 (2006) 253-255
25. Kordower J.H., Kanaan N.M., Chu Y., Suresh Babu R., Stansell III J., Terpstra B.T., et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol 60 (2006) 264-268
26. Manning-Bog A.B., Reaney S.H., Chou V.P., Johnston L.C., McCormack A.L., Johnston J., et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol 60 (2006) 256-260
27. Hampe C., Ardila-Osorio H., Fournier M., Brice A., and Corti O. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum Mol Genet 15 (2006) 2059-2075
28. Wang C., Ko H.S., Thomas B., Tsang F., Chew K.C., Tay S.P., et al. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum Mol Genet 14 (2005) 3885-3897
29. Tan E.K., Puong K.Y., Chan D.K., Yew K., Fook-Chong S., Shen H., et al. Impaired transcriptional upregulation of Parkin promoter variant under oxidative stress and proteasomal inhibition: clinical association. Hum Genet 118 (2005) 484-488
30. Biasini E., Fioriti L., Ceglia I., Invernizzi R., Bertoli A., Chiesa R., et al. Proteasome inhibition and aggregation in Parkinson's disease: a comparative study in untransfected and transfected cells. J Neurochem 88 (2004) 545-553